Development of resistance in castration-resistant prostate cancer (CRPC) involves epigenetic pathways.A new study in PLOS Biology demonstrates 510 that combined therapy targeting enhancer of zeste homolog 2 (EZH2) and histone deacetylases (HDACs) may sensitize CRPC to both epigenetic and standard therapies.Development of resistance in castration-resistant prostate cancer (CRPC) involves epigenetic pathways involving EZH2 and HDACs.
This Primer explores a PLOS Biology study showing that combined epigenetic therapy targeting these enzymes can activate cellular stress QUICK-BLAST pathways, which may sensitize CRPC to both epigenetic and standard therapies.